AR126053A1 - Derivados de triazina - Google Patents
Derivados de triazinaInfo
- Publication number
- AR126053A1 AR126053A1 ARP220101456A ARP220101456A AR126053A1 AR 126053 A1 AR126053 A1 AR 126053A1 AR P220101456 A ARP220101456 A AR P220101456A AR P220101456 A ARP220101456 A AR P220101456A AR 126053 A1 AR126053 A1 AR 126053A1
- Authority
- AR
- Argentina
- Prior art keywords
- halo
- alkyl
- optionally substituted
- cycloalkyl
- haloalkyl
- Prior art date
Links
- 150000003918 triazines Chemical class 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 125000001188 haloalkyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- -1 -OH Chemical group 0.000 abstract 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 abstract 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003054 catalyst Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000002825 nitriles Chemical class 0.000 abstract 1
- 229910052763 palladium Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21177660 | 2021-06-04 | ||
| EP21188639 | 2021-07-30 | ||
| EP21215875 | 2021-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126053A1 true AR126053A1 (es) | 2023-09-06 |
Family
ID=82115763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101456A AR126053A1 (es) | 2021-06-04 | 2022-06-02 | Derivados de triazina |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20240132471A1 (OSRAM) |
| EP (1) | EP4347571B1 (OSRAM) |
| JP (2) | JP7705963B2 (OSRAM) |
| KR (1) | KR20240019083A (OSRAM) |
| AR (1) | AR126053A1 (OSRAM) |
| AU (1) | AU2022287224A1 (OSRAM) |
| BR (1) | BR112023025318A2 (OSRAM) |
| CA (1) | CA3216026A1 (OSRAM) |
| CL (1) | CL2023003491A1 (OSRAM) |
| CO (1) | CO2023016212A2 (OSRAM) |
| CR (1) | CR20230566A (OSRAM) |
| IL (1) | IL307201A (OSRAM) |
| MX (1) | MX2023013998A (OSRAM) |
| PE (1) | PE20240928A1 (OSRAM) |
| TW (1) | TW202313577A (OSRAM) |
| WO (1) | WO2022253936A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| BR112023022451A2 (pt) * | 2021-04-28 | 2024-01-02 | Astellas Pharma Inc | Composto triazina substituído |
| BR112023025318A2 (pt) * | 2021-06-04 | 2024-02-27 | Hoffmann La Roche | Derivados de triazina e seu uso no tratamento do câncer |
| CA3246797A1 (en) * | 2022-01-07 | 2025-07-08 | Transthera Sciences (Nanjing) , Inc. | Nlrp3 inflammasome inhibitor and application thereof |
| US20260015353A1 (en) * | 2022-07-21 | 2026-01-15 | Hoffmann-La Roche Inc. | Novel compounds |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| CN121045190A (zh) * | 2022-11-04 | 2025-12-02 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| CR20250215A (es) * | 2022-12-07 | 2025-06-26 | Hoffmann La Roche | Compuestos novedosos como moduladores de la inhibición de nlrp3 |
| KR20250158072A (ko) * | 2023-03-20 | 2025-11-05 | 인실리코 메디신 아이피 리미티드 | Nlrp3 인플라마좀 억제제 및 이의 용도 |
| KR20250162889A (ko) * | 2023-03-23 | 2025-11-19 | 청두 제니타르 바이오메디컬 테크놀로지 컴퍼니 리미티드 | 트리아진계 화합물 및 이의 용도 |
| TW202448448A (zh) * | 2023-04-19 | 2024-12-16 | 瑞士商赫孚孟拉羅股份公司 | 新穎化合物 |
| CR20250409A (es) * | 2023-04-19 | 2025-10-30 | Hoffmann La Roche | Derivados de oxazolo[4,5-b]pirazina y oxazolo[4,5-b]piridina como inhibidores de nlpr3 para el tratamiento de, por ejemplo, enfermedades inflamatoria |
| EP4719599A1 (en) | 2023-06-02 | 2026-04-08 | Merck Sharp & Dohme LLC | 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3 |
| CN121586712A (zh) * | 2023-07-28 | 2026-02-27 | 豪夫迈·罗氏有限公司 | 新颖化合物 |
| KR20250030934A (ko) * | 2023-08-25 | 2025-03-05 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025252772A1 (en) * | 2024-06-06 | 2025-12-11 | F. Hoffmann-La Roche Ag | Triazine derivatives |
| WO2026046981A1 (en) | 2024-08-28 | 2026-03-05 | F. Hoffmann-La Roche Ag | Solid forms of 5-[3-[[(3r)-1-ethyl-3-piperidyl]amino]-5-methyl-1,2,4-triazin-6-yl]-2,3- dihydrobenzofuran-4-ol |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102636383B1 (ko) * | 2017-08-04 | 2024-02-14 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| TW201910316A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| PE20210050A1 (es) | 2017-11-09 | 2021-01-08 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida |
| AU2019243048A1 (en) * | 2018-03-27 | 2020-10-15 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| US12168012B2 (en) | 2018-07-25 | 2024-12-17 | Novartis Ag | NLRP3 inflammasome inhibitors |
| CN119320388A (zh) * | 2019-02-04 | 2025-01-17 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| JP7843705B2 (ja) | 2020-01-22 | 2026-04-10 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物 |
| ES3064621T3 (en) | 2020-03-27 | 2026-04-27 | Tenvie Therapeutics Inc | Substituted pyridazine compound |
| US20240391895A1 (en) | 2020-12-25 | 2024-11-28 | Tuojie Biotech (Shanghai) Co., Ltd. | Pyridazine-containing compound and medicinal use thereof |
| WO2022166890A1 (zh) | 2021-02-08 | 2022-08-11 | 南京明德新药研发有限公司 | 取代的哒嗪苯酚类衍生物 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| BR112023022451A2 (pt) | 2021-04-28 | 2024-01-02 | Astellas Pharma Inc | Composto triazina substituído |
| BR112023025318A2 (pt) * | 2021-06-04 | 2024-02-27 | Hoffmann La Roche | Derivados de triazina e seu uso no tratamento do câncer |
| US20240294542A1 (en) | 2021-06-05 | 2024-09-05 | Transthera Sciences (Nanjing), Inc. | Nlrp3 inflammasome inhibitor and application thereof |
| HRP20251513T1 (hr) | 2021-07-02 | 2026-01-02 | Astrazeneca Ab | Inhibitori inflamasoma nlrp3 |
| WO2023028536A1 (en) | 2021-08-25 | 2023-03-02 | Ptc Therapeutics, Inc. | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 |
| WO2023066377A1 (zh) | 2021-10-22 | 2023-04-27 | 索智生物科技（浙江）有限公司 | 一种含氮化合物、其制备方法及应用 |
| CA3246797A1 (en) | 2022-01-07 | 2025-07-08 | Transthera Sciences (Nanjing) , Inc. | Nlrp3 inflammasome inhibitor and application thereof |
| IL315842A (en) | 2022-03-25 | 2024-11-01 | Ventus Therapeutics U S Inc | Pyrido-[4,3-D]pyridazine amine derivatives are useful as NLRP3 derivatives |
| TW202432551A (zh) | 2022-10-26 | 2024-08-16 | 日商安斯泰來製藥股份有限公司 | 稠環嗒嗪衍生物 |
| CN115621720A (zh) * | 2022-10-27 | 2023-01-17 | 永道射频技术股份有限公司 | 一种应用于rfid读写器的全息超材料阵列天线 |
| CN121045190A (zh) | 2022-11-04 | 2025-12-02 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| JP2026503239A (ja) | 2022-12-28 | 2026-01-28 | アストラゼネカ・アクチエボラーグ | Ｎｌｒｐ３インフラマソーム阻害剤 |
| CN120435466A (zh) | 2023-02-17 | 2025-08-05 | 成都赜灵生物医药科技有限公司 | 六元氮杂环类化合物及其用途 |
-
2022
- 2022-06-02 BR BR112023025318A patent/BR112023025318A2/pt unknown
- 2022-06-02 IL IL307201A patent/IL307201A/en unknown
- 2022-06-02 EP EP22731614.8A patent/EP4347571B1/en active Active
- 2022-06-02 JP JP2023572751A patent/JP7705963B2/ja active Active
- 2022-06-02 MX MX2023013998A patent/MX2023013998A/es unknown
- 2022-06-02 KR KR1020237039328A patent/KR20240019083A/ko active Pending
- 2022-06-02 CR CR20230566A patent/CR20230566A/es unknown
- 2022-06-02 CA CA3216026A patent/CA3216026A1/en active Pending
- 2022-06-02 AR ARP220101456A patent/AR126053A1/es unknown
- 2022-06-02 TW TW111120574A patent/TW202313577A/zh unknown
- 2022-06-02 WO PCT/EP2022/064995 patent/WO2022253936A1/en not_active Ceased
- 2022-06-02 PE PE2023003133A patent/PE20240928A1/es unknown
- 2022-06-02 AU AU2022287224A patent/AU2022287224A1/en active Pending
-
2023
- 2023-11-23 CL CL2023003491A patent/CL2023003491A1/es unknown
- 2023-11-29 CO CONC2023/0016212A patent/CO2023016212A2/es unknown
- 2023-11-30 US US18/524,678 patent/US20240132471A1/en not_active Abandoned
-
2025
- 2025-02-25 US US19/063,141 patent/US12421209B2/en active Active
- 2025-03-26 JP JP2025051003A patent/JP2025098157A/ja active Pending
- 2025-05-16 US US19/210,925 patent/US20250276958A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240132471A1 (en) | 2024-04-25 |
| WO2022253936A1 (en) | 2022-12-08 |
| CO2023016212A2 (es) | 2023-12-11 |
| PE20240928A1 (es) | 2024-04-30 |
| EP4347571B1 (en) | 2026-04-22 |
| AU2022287224A1 (en) | 2023-09-21 |
| CA3216026A1 (en) | 2022-12-08 |
| KR20240019083A (ko) | 2024-02-14 |
| JP2024522494A (ja) | 2024-06-21 |
| BR112023025318A2 (pt) | 2024-02-27 |
| JP7705963B2 (ja) | 2025-07-10 |
| JP2025098157A (ja) | 2025-07-01 |
| MX2023013998A (es) | 2023-12-11 |
| CR20230566A (es) | 2024-01-22 |
| EP4347571A1 (en) | 2024-04-10 |
| US20250197370A1 (en) | 2025-06-19 |
| IL307201A (en) | 2023-11-01 |
| US12421209B2 (en) | 2025-09-23 |
| US20250276958A1 (en) | 2025-09-04 |
| TW202313577A (zh) | 2023-04-01 |
| CL2023003491A1 (es) | 2024-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR125818A1 (es) | Inhibidores de nlrp3 | |
| AR127705A1 (es) | Heterociclos inhibidores de nlrp3 | |
| AR112834A1 (es) | Derivados de rapamicina | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR127704A1 (es) | Derivados de piridazina inhibidores de nlrp3 | |
| ECSP10010405A (es) | Procesos e intermediarios para la preparacion de derivados de acido 5-bifenil-4-il-2-metilpentanoico | |
| BR112012006572A2 (pt) | inibidores de demetilase-1 de lisina específicos e seu uso | |
| CU20160030A7 (es) | Compuestos éteres de arilo yútiles para tratar cancer de célula renal | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| AR094314A1 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
| AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
| AR063706A1 (es) | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. | |
| AR076486A1 (es) | Inhibidores de fosfoinositida 3 kinasa y composiciones farmaceuticas que los contienen. | |
| AR117229A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR066153A1 (es) | Derivados de piperidina / piperazina | |
| AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 | |
| PE20240928A1 (es) | Derivados de triazina y su uso en el tratamiento del cancer | |
| AR066191A1 (es) | Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona | |
| AR066154A1 (es) | Derivados de piperidina / piperazina | |
| AR094852A1 (es) | Oestra-1,3,5(10),16-tetraeno-3-carboxamidas | |
| AR125026A1 (es) | Inhibidores del sarcómero cardíaco | |
| PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
| AR051795A1 (es) | Derivados de hidantoina inhibidores de metaloproteinasas | |
| AR046753A1 (es) | Derivados de benzoxazina y usos de los mismos | |
| PE20250419A1 (es) | Compuestos antivirales y metodos de elaboracion y uso de los mismos |